World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
75303
World Ranking
3164
National Ranking
171

Overview

Carsten Denkert is affiliated with Philipp University of Marburg in Germany and has contributed extensively to the fields of oncology and cancer research. Their work primarily focuses on breast cancer treatment, cancer genomics and diagnostics, cancer immunotherapy and biomarkers, and targeted cancer therapies, including HER2/EGFR pathways and PARP inhibition.

The scientist has published in numerous well-regarded journals with a strong record in clinical and translational cancer research. Frequent publication venues include:

  • Annals of Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Cancers

Denkert's research spans multiple subfields such as oncology, cancer research, pulmonary and respiratory medicine, molecular biology, and genetics, with over 500 publications in medicine and a significant number in biochemistry, genetics, and molecular biology.

Key topics covered in Denkert's work reflect a focus on breast cancer and advanced therapeutic strategies:

  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • PARP inhibition in cancer therapy

Recent publications include:

  • "Pembrolizumab for Early Triple-Negative Breast Cancer" (2020), New England Journal of Medicine
  • "Breast cancer" (2021), The Lancet
  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021" (2021), Annals of Oncology
  • "Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group" (2020), JNCI Journal of the National Cancer Institute
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up" (2023), Annals of Oncology

Frequent collaborators in Denkert's research efforts include:

  • Sibylle Loibl
  • Peter A. Fasching
  • Valentina Nekljudova
  • Michael Untch
  • Andreas Schneeweiß

Best Publications

  • An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

    Balazs Györffy;Andras Lanczky;Aron C. Eklund;Carsten Denkert

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

    Carsten Denkert;Sibylle Loibl;Aurelia Noske;Marc Roller

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    S. Loi;S. Loi;S. Michiels;S. Michiels;R. Salgado;N. Sirtaine

  • Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

    Carsten Denkert;Gunter von Minckwitz;Jan C. Brase;Bruno V. Sinn

  • Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

    Jan Budczies;Frederick Klauschen;Bruno V. Sinn;Balázs Győrffy

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas;Roberto Salgado;Carsten Denkert;Christos Sotiriou

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

    Sherene Loi;Damien Drubay;Sylvia Adams;Giancarlo Pruneri

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Molecular alterations in triple-negative breast cancer—the road to new treatment strategies

    Carsten Denkert;Cornelia Liedtke;Andrew Tutt;Gunter von Minckwitz

  • RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

    Sherene Loi;Sherene Loi;Sathana Dushyanthen;Paul A. Beavis;Roberto Salgado

  • Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial

    Roberto Salgado;Carsten Denkert;Christine Campbell;Peter Savas

  • A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

    S. Loibl;M. Untch;N. Burchardi;J. Huober

  • Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

    Gunter von Minckwitz;Holger Eidtmann;Mahdi Rezai;Peter A. Fasching

Frequent Co-Authors

Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Manfred Dietel
Manfred Dietel Charité - University Medicine Berlin
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Wilko Weichert
Wilko Weichert Technical University of Munich
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Jalid Sehouli
Jalid Sehouli Charité - University Medicine Berlin
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Jens Huober
Jens Huober Kantonsspital St. Gallen
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open up versatile career pathways in healthcare beyond traditional medical school. Many students are now considering advanced degrees in healthcare administration, nursing practice, and pharmacy—often pursuing these qualifications online for added flexibility and affordability.

For those interested in leadership roles, enrolling in the cheapest mha programs online or researching other cheap mha programs can provide a strong foundation in healthcare management. These programs allow graduates to oversee hospitals, clinics, or health systems, and are especially attractive for their cost-effectiveness.

Nursing professionals intending to elevate their scope of practice may look towards the best online bsn to dnp programs. These pathways equip registered nurses with critical skills in leadership, research, and clinical expertise, preparing them for top advanced practice roles.

Additionally, those driven toward the pharmaceutical sector might consider online pharmacy programs. These doctoral programs focus on medication therapy management, patient care, and healthcare innovation, catering to aspiring pharmacists who need to balance studies with work or family commitments.

Best Scientists Citing Carsten Denkert

Trending Scientists